Stephens downgraded Avid Bioservices (CDMO) to Equal Weight from Overweight with a price target of $12.50, up from $12, after Avid filed its merger proxy associated with GHO/Ampersand’s proposed acquisition. It seems like this deal is likely to go through as proposed, the analyst tells investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDMO: